Placebo 1 (2) Liutkus et al, 2010 (66) FAS Exenatide 10 µg BID 4 (4) Insulin glargine QD + lixisenatide 12 (3) LixiLan-O (67) Insulin glargine QD mITT 9 (2) Lixisenatide 20 μg QD 21 (9) Semaglutide 0.5 mg QW SUSTAIN 2† (22) Semaglutide 1.0 mg QW FAS NR Sitagliptin 100 mg QD Semaglutide 1.0 mg QW SUSTAIN 3† (23) FAS NA Exenatide 2 mg QW Semaglutide 0.5 mg QW 19 (6) SUSTAIN 4† (27) Semaglutide 1.0 mg QW FAS 27 (8) Insulin glargine 5 (1) Semaglutide 0.5 mg QW Semaglutide 1.0 mg QW SUSTAIN 7† (27) FAS NR Dulaglutide 0.75 mg QW Dulaglutide 1.5 mg QW Sitagliptin 100 mg QD 5 (3) Van Gaal et al, 2014 (68) ITT Lixisenatide 20 µg QD 4 (3) Liraglutide 1.8 mg QD 12 (7) Zang et al, 2016 (69) FAS Sitagliptin 100 mg QD 3 (2) Trials shaded in grey were excluded from the base case analysis due to heterogeneity. Abbreviations: AE, adverse event; BID, twice daily; CI, confidence interval; FAS, full analysis set; ITT, intention to treat; mITT, modified ITT; NR, not reported; PP, per protocol; QD, once-daily; QW, once-weekly. †Data from the SUSTAIN clinical trials were taken from the clinical study reports.
Liutkus et al, 2010 (66) Placebo FAS 1 (2) Exenatide 10 µg BID 4 (4) LixiLan-O (67) Insulin glargine QD + lixisenatide mITT 12 (3) Insulin glargine QD 9 (2) Lixisenatide 20 μg QD 21 (9) SUSTAIN 2† (22) Semaglutide 0.5 mg QW FAS NR Semaglutide 1.0 mg QW Sitagliptin 100 mg QD SUSTAIN 3† (23) Semaglutide 1.0 mg QW FAS NA Exenatide 2 mg QW SUSTAIN 4† (27) Semaglutide 0.5 mg QW FAS 19 (6) Semaglutide 1.0 mg QW 27 (8) Insulin glargine 5 (1) SUSTAIN 7† (27) Semaglutide 0.5 mg QW FAS NR Semaglutide 1.0 mg QW Dulaglutide 0.75 mg QW Dulaglutide 1.5 mg QW Van Gaal et al, 2014 (68) Sitagliptin 100 mg QD ITT 5 (3) Lixisenatide 20 µg QD 4 (3) Zang et al, 2016 (69) Liraglutide 1.8 mg QD FAS 12 (7) Sitagliptin 100 mg QD 3 (2) Trials shaded in grey were excluded from the base case analysis due to heterogeneity. Abbreviations: AE, adverse event; BID, twice daily; CI, confidence interval; FAS, full analysis set; ITT, intention to treat; mITT, modified ITT; NR, not reported; PP, per protocol; QD, once-daily; QW, once-weekly. †Data from the SUSTAIN clinical trials were taken from the clinical study reports.
13300_2018_424_MOESM1_ESM.docx